JODI CRINER: Open Payments
NPI 1841944527 · SMITHFIELD, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,662 in 70 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,023 · 2025 $1,662
Food & beverage: $1,662
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $393 |
| Gilead Sciences, Inc. | 9 | $231 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $220 |
| ABBVIE INC. | 14 | $217 |
| QOL Medical, LLC | 5 | $168 |
| Ardelyx, Inc. | 4 | $124 |
| Lilly USA, LLC | 3 | $84 |
| Janssen Biotech, Inc. | 2 | $66 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| Braintree Laboratories, Inc. | 1 | $28 |
Products named: ENTYVIO, XIFAXAN, Sucraid, IBSRELA, GATTEX, OMVOH, TREMFYA, RINVOQ.
Industry payments across RI — which companies pay providers there.
